Yao Chou Tsai

Dr. Yao Chou Tsai

Division of Urology, Department of surgery, Taipei Tzuchi Hospital, The Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan.
+1
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2010 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
SCShiu-Dong Chung
Shiu-Dong Chung
CHChao-Yuan Huang
Chao-Yuan Huang
SWShuo-Meng Wang
Shuo-Meng Wang
HTHuai-Ching Tai
Huai-Ching Tai
YTYao Chou Tsai
Yao Chou Tsai
SCShih-Chieh Chueh
Shih-Chieh Chueh

13 March 2007 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
YTYao Chou Tsai
Yao Chou Tsai
CWChia Chang Wu
Chia Chang Wu
SYStephen Shei-Dei Yang
Stephen Shei-Dei Yang

1 September 2015 in Urological Science
Verified
Journal Article
Open access
YTYao Chou Tsai
Yao Chou Tsai
HKHann-Chorng Kuo
Hann-Chorng Kuo
Ketamine, an n-methyl-d-aspartic acid receptor complex antagonist, has been used as an anesthetic and/or analgesic. However, in the past decade, ketamine has been illegally available as a recreational drug in Asian countries and Taiwan. Due to the characteristic of being short-acting, youngsters widely assume that ketamine is not as harmful as other drugs, such as heroin. Consequently, many young patients used this drug for a longer duration before they presented with severe urinary frequency and urgency symptoms. Subsequently, other cases have been reported in Taiwan, Hong Kong, Singapore, Malaysia, and Europe. Ketamine abuse is increasing, with rates of 0.30% in 2006 to 0.40% in 2007 among those in the 16–59 year age group. In general, affected patients tend to be young with a peak age range of 16–35 years. The incidence of lower urinary tract symptoms in ketamine abuse patients is around 30%. The actual underlying pathomechanism of ketamine cystitis (KC) and associated pelvic pain remains unclear. It is speculated that chronic contact and stimulation to the bladder or ureteral mucosa due to metabolites of ketamine will result in submucosal edema, vascular ectasia, fibrosis, detrusor muscle inflammation, and fibrosis. Presentations of KC include remarkable dysuria, urinary frequency/urgency, urge incontinence, and bladder pain. Urine culture usually fails to yield any microbiology in KC with bladder pain alone. The majority of patients can enjoy clinical improvement after cessation of ketamine and urological treatment similar to interstitial cystitis/bladder pain syndrome (IC/BPS). However, patients who are still abusing ketamine and/or who have a longer duration of ketamine abuse might suffer from severe bladder pain, which does not respond to empirical oral or intravesical treatments such as hyaluronic acid. Among these patients, most have a remarkably impaired quality of life and are at risk of developing upper urinary tract damage, including hydronephrosis and kidney injury. To reduce bladder pain, improve quality of life, and avoid further deterioration of renal function, surgical intervention might be indicated

3 June 2011 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
SCShiu-Dong Chung
Shiu-Dong Chung
CHChao-Yuan Huang
Chao-Yuan Huang
SWShuo-Meng Wang
Shuo-Meng Wang
SHShun-Fa Hung
Shun-Fa Hung
YTYao Chou Tsai
Yao Chou Tsai
HYHong-Jeng Yu
Hong-Jeng Yu

17 February 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YCYung-Tai Chen
Yung-Tai Chen
CYChih-Chin Yu
Chih-Chin Yu
HYHsin-Chih Yeh
Hsin-Chih Yeh
HLHsiang-Ying Lee
Hsiang-Ying Lee
YJYuan-Hong Jiang
Yuan-Hong Jiang
YTYao Chou Tsai
Yao Chou Tsai
Our aim was to analyze the clinical and survival differences among patients who underwent the two main treatment modalities, endoscopic ablation and radical nephroureterectomy. This study examined all patients who had undergone endoscopic management and RNU between Jul. 1988 and Mar. 2019 from the Taiwan UTUC registry. The inclusion criteria were low stage UTUC in RNU and all cases in endoscopic managed UTUC with a curative intent. The demographic and clinical characteristics were included for analysis. In total, 84 cases in the endoscopic group and 272 cases in the RNU group were enrolled for final analysis. The median follow-up period were 33.5 and 42.0 months in endoscopic and RNU group, respectively (p = 0.082). Comparison of Kaplan–Meier estimated survival curves between groups, the endoscopic group was associated with similar overall survival (OS), cancer specific survival (CSS), and intravesical recurrence free survival (IVRS) but demonstrated inferior disease free survival (DFS) (p = 0.188 for OS, p = 0.493 for CSS and p < 0.001 for DFS). Endoscopic management of UTUC was as safe as RNU in UTUC endemic region.

30 June 2021 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
CPCarol Chiung-Hui Peng
Carol Chiung-Hui Peng
Yu-Kang TuYu-Kang Tu
Yu-Kang Tu
GLGin Yi Lee
Gin Yi Lee
RCRachel Huai-En Chang
Rachel Huai-En Chang
YHYuting Huang
Yuting Huang
KMKashif Munir
Kashif Munir
Context Whether proton pump inhibitors (PPI) can improve glycemic control among individuals with diabetes or decrease the risk of incident diabetes in the general population is unclear. Objective To evaluate the impact of PPI therapy on glycemic control among individuals with diabetes and the risk of diabetes among those without diabetes. Results PubMed, Embase, Scopus, and ClinicalTrials.gov were searched from inception to November 21, 2020. We included studies comparing glycosylated hemoglobin (HbA1c) or fasting blood glucose (FBG) among individuals with diabetes treated with and without PPI therapy as an add-on to standard therapy. Studies evaluating the risk of incident diabetes among individuals taking PPI were assessed. We performed dual independent review, data extraction, and quality assessment. Weighted mean differences between groups or relative risks were imputed using random-effects models. Results Seven studies (n = 342) for glycemic control and 5 studies (n = 244 439) for risk of incident diabetes were included. Compared with standard therapy, add-on PPI was associated with a significant decrease in HbA1c (WMD, −0.36 %; 95% CI, −0.68 to −0.05; P = 0.025) and FBG (WMD, −10.0 mg/dL; 95% CI, −19.4 to −0.6; P = 0.037). PPI use did not reduce the risk of incident diabetes (pooled RR, 1.10; 95% CI, 0.89 to 1.34; P = 0.385). Conclusion Add-on PPI improved glycemic indices among individuals with diabetes but did not alter the risk of incident diabetes. The effects of PPI on glycemic control should be considered when prescribing antacids to patients with diabetes.